What Kun Jin knows will be more important. If he were the FDA biostatistician in charge of reviewing the submissions for Aduhelm and Leqembi, as has been stated here, he is the perfect person to make the case that blarcamesine is statistically superior to either of them. No one would have better credentials for that role.